A new way of treating serious asthma and chronic obstructive pulmonary disease (COPD) attacks could be a “game-changer” and is the first leap in treatment for 50 years, researchers say. Offering patients an injection is more effective than the current care of steroid tablets and cuts the need for further treatment by 30%, according to a study. Benralizumab is a monoclonal antibody that targets specific white blood cells, called eosinophils, to reduce lung inflammation.
It is currently used as a repeat treatment for severe asthma at a low dose, but a new clinical trial has found that a higher single dose can be very effective if injected at the time of a flare-up. The findings, published in the Lancet Respiratory Medicine, included 158 people who needed medical attention in A&E for their asthma or COPD attack (COPD is a group of lung conditions that cause breathing difficulties). Patients were given a quick blood test to see what type of attack they were having, with those suffering an “eosinophilic exacerbation” involving eosinophils (a type of white blood cell) being suitable for treatment.
Around 50% of asthma attacks are eosinophilic exacerbations, as are 30% of COPD ones, according to the scientists. The clinical trial, led by King’s College London and carried out at Oxford University Hospitals NHS Foundation Trust and Guy’s and St Thomas’ NHS Foundation Trust, saw patients randomly split into three groups. One group received the benralizumab injection and d.
